# Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control

Study · id `cardio:ct-nct01066039` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01066039](<https://clinicaltrials.gov/study/NCT01066039>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01066039

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.

## Technical summary

Registry record NCT01066039. Allocation not applicable; no masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2014-07-04.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 202 participants (enrolled count; ClinicalTrials.gov record NCT01066039, source copy `cardio:ctgov-nct01066039-2014-07-04`, retrieved 2026-10-26)
- Start date: 2010-04 (registry gives no type) (ClinicalTrials.gov record NCT01066039, source copy `cardio:ctgov-nct01066039-2014-07-04`, retrieved 2026-10-26)
- Primary completion: 2013-04 (actual) (ClinicalTrials.gov record NCT01066039, source copy `cardio:ctgov-nct01066039-2014-07-04`, retrieved 2026-10-26)
- Completion: 2013-04 (actual) (ClinicalTrials.gov record NCT01066039, source copy `cardio:ctgov-nct01066039-2014-07-04`, retrieved 2026-10-26)
- Results first posted: 2014-07-04 (ClinicalTrials.gov record NCT01066039, source copy `cardio:ctgov-nct01066039-2014-07-04`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01066039, source copy `cardio:ctgov-nct01066039-2014-07-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01066039-2014-07-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control
- Acronym: GIANT
- Condition: Hypertension
- Condition: Diabetes Mellitus, Type II
- Intervention (Drug): Bisoprolol
- Lead sponsor: Merck KGaA, Darmstadt, Germany
- Lead sponsor class: INDUSTRY
- Collaborator: Merck Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Bisoprolol (`cardio:bisoprolol`)
- Registry intervention is a member of this class by a sourced record link: Beta-blockers (drug class) (`cardio:beta-blockers`)
- Registry lists this organization as the lead sponsor: Merck KGaA, Darmstadt, Germany (`cardio:org-merck-kgaa-darmstadt-germany`)

## Provenance

Content hash: f67cb28cb2a2138238a061f13e5a84bbac89d711ef8467f9c47404e956aa0c0b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
